SRPTSarepta Therapeutics Inc (NASDAQ:SRPT) granted equity awards on November 30, 2016, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to seven individuals hired by Sarepta in November 2016. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4).

The employees received, in the aggregate, options to purchase 22,875 shares of Sarepta’s common stock. The options have an exercise price of $34.26 per share, which is equal to the closing price of Sarepta’s common stock on November 30, 2016. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates. (Original Source)

Shares of Sarepta Therapeutics closed today at $34.26, down $2.46 or -6.70%. SRPT has a 1-year high of $63.73 and a 1-year low of $8. The stock’s 50-day moving average is $51.51 and its 200-day moving average is $29.74.

On the ratings front, Sarepta has been the subject of a number of recent research reports. In a report released yesterday, Baird analyst Brian Skorney reiterated a Buy rating on SRPT, with a price target of $102, which implies an upside of 198% from current levels. Separately, on November 17, JMP’s Liisa Bayko reiterated a Buy rating on the stock .

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Brian Skorney and Liisa Bayko have a yearly average return of 2.4% and 5.9% respectively. Skorney has a success rate of 46% and is ranked #1284 out of 4241 analysts, while Bayko has a success rate of 51% and is ranked #689.

Sentiment on the street is mostly bullish on SRPT stock. Out of 15 analysts who cover the stock, 12 suggest a Buy rating and 3 recommend to Hold the stock. The 12-month average price target assigned to the stock is $74.57, which represents a potential upside of 118% from where the stock is currently trading.

Sarepta Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the discovery and development of unique RNA-based therapeutics for the treatment of rare and infectious diseases. The company is primarily focused on rapidly advancing the development of its potentially disease modifying duchenne muscular dystrophy drug candidates.